Evidence map›Paper›PMID 27285995›Full record

ArticlePloS one2016

Anti-Breast Cancer Potential of Quercetin via the Akt/AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Cascade.

Amilcar Rivera Rivera, Linette Castillo-Pichardo, Yamil Gerena, Suranganie Dharmawardhane

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. A Bibenzyl fromAntioxidants (Basel, Switzerland) · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. The Effect ofMolecules (Basel, Switzerland) · 2024
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Amilcar Rivera RiveraDepartment of Biochemistry, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.
Linette Castillo-PichardoDepartment of Biochemistry, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.
Yamil GerenaDepartment of Pharmacology and Toxicology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.
Suranganie DharmawardhaneDepartment of Biochemistry, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.
University of Puerto Rico, Medical Sciences Campus · PR

Funding

SCIENCE AND TECHNOLOGY COMPETENCY & EDUCATION CORE (STCE)P20GM103475 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CARMEN LYDIA CADILLA · 2012 to 2026
$52.9M
UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Ilka C Rios · 2002 to 2026
$36.9M
RISE Option III: MBRS RISE at the UPR Medical Sciences CampusR25GM061838 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CADILLA, CARMEN LYDIA · 2000 to 2021
$25.5M
TRANSLATIONAL PROTEOMICS CENTERG12MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FERNANDEZ-REPOLLET, EMMA · 2012 to 2016
$11.0M
UNIVERSIDAD CENTRAL DEL CARIBE BIOMEDICAL RESEARCH CENTERSG12MD007583 · NIMHD · UNIVERSIDAD CENTRAL DEL CARIBE · PI RODRIGUEZ, JOSE GINEL · 2012 to 2016
$8.4M
Targeting breast cancer progressionSC3GM084824 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI DHARMAWARDHANE, SURANGANIE · 2008 to 2021
$1.6M
NCI NIH HHS U54 CA096297NIGMS NIH HHS P20 GM103475NIGMS NIH HHS R25 GM061838NIGMS NIH HHS SC3 GM084824NIMHD NIH HHS G12 MD007583NIMHD NIH HHS G12 MD007600
6 · The paper itself

Abstract

The Akt/adenosine monophosphate protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway has emerged as a critical signaling nexus for regulating cellular metabolism, energy homeostasis, and cell growth. Thus, dysregulation of this pathway contributes to the development of metabolic disorders such as obesity, type 2diabetes, and cancer. We previously reported that a combination of grape polyphenols (resveratrol, quercetin and catechin: RQC), at equimolar concentrations, reduces breast cancer (BC) growth and metastasis in nude mice, and inhibits Akt and mTOR activities and activates AMPK, an endogenous inhibitor of mTOR, in metastatic BC cells. The objective of the present study was to determine the contribution of individual polyphenols to the effect of combined RQC on mTOR signaling. Metastatic BC cells were treated with RQC individually or in combination, at various concentrations, and the activities (phosphorylation) of AMPK, Akt, and the mTOR downstream effectors, p70S6 kinase (p70S6K) and 4E binding protein (4EBP1), were determined by Western blot. Results show that quercetin was the most effective compound for Akt/mTOR inhibition. Treatment with quercetin at 15μM had a similar effect as the RQC combination in the inhibition of BC cell proliferation, apoptosis, and migration. However, cell cycle analysis showed that the RQC treatment arrested BC cells in the G1 phase, while quercetin arrested the cell cycle in G2/M. In vivo experiments, using SCID mice with implanted tumors from metastatic BC cells, demonstrated that administration of quercetin at 15mg/kg body weight resulted in a ~70% reduction in tumor growth. In conclusion, quercetin appears to be a viable grape polyphenol for future development as an anti BC therapeutic.

Indexed as

AMP-Activated Protein KinasesAnimalsAntineoplastic Agents, PhytogenicBreastBreast NeoplasmsCatechinCell CycleCell Line, TumorCell ProliferationFemaleHumansMice, NudeMice, SCIDNeoplasm MetastasisProto-Oncogene Proteins c-aktQuercetinAMP-Activated Protein KinasesAntineoplastic Agents, PhytogenicCatechinProto-Oncogene Proteins c-aktQuercetinResveratrolStilbenesTOR Serine-Threonine Kinases

Identifiers

PMID27285995
PMCPMC4902235
OpenAlexW2415913163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.